(Q35623064)

9 August 2017

1 reference

title

Clinical pharmacodynamics of quinolones (English)

1 reference

9 August 2017

0 references

1 reference

2

Sujata M Bhavnani

1 reference

9 August 2017

1

Paul G Ambrose

1 reference

9 August 2017

Robert C Owens

3

1 reference

9 August 2017

1 September 2003

1 reference

Infectious Disease Clinics of North America

9 August 2017

1 reference

9 August 2017

17

1 reference

9 August 2017

3

1 reference

9 August 2017

529-543

1 reference

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Pharmacodynamics of fluoroquinolones in experimental models of endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

"Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Does the dose matter?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Pharmacodynamics to combat resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases: Report from the ARREST Program

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900061-8

7 January 2021

10.1016/S0891-5520(03)00061-8

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14711075